Research record
Leukemia subtype and testing map
Before comparing leukemia options, families need the exact subtype and the pending/completed tests: blood count, marrow, flow cytometry, cytogenetics, FISH, and molecular testing.
What this is
Before comparing leukemia options, families need the exact subtype and the pending/completed tests: blood count, marrow, flow cytometry, cytogenetics, FISH, and molecular testing.
Why it may come up
- new diagnosis
- relapse
- second opinion
- trial search
What not to assume
- Do not combine AML, ALL, CLL, and CML into one treatment pathway.
- Do not use melanoma-style stage/mutation logic for leukemia.
- No treatment ranking or regimen selection.
At a glance
Leukemia subtype and testing map
- Type
- diagnostic-context
- Mutation result
- varies by subtype
- Where
- Global
- Evidence status
- Source gives context
- Last checked
- 2026-05-21
What we know
- NCI separates leukemia treatment information by subtype, including AML, ALL, CLL, and CML.
- The MatchMedi leukemia module should not force solid-tumor stage or mutation assumptions onto blood cancers.
What is unclear
- Country-specific leukemia drug access, reimbursement, and transplant/CAR-T pathways are not mapped yet.
- Korean clinical leukemia pages need authoritative Korean source mapping before they become treatment pages.
Questions to ask
- What exact leukemia subtype is written on the report?
- Which tests are pending or completed: flow cytometry, cytogenetics, FISH, molecular testing, or marrow pathology?
- Is the current conversation new diagnosis, remission, relapse, transplant, CAR-T, or trial search?